A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally

Clinical Therapeutics

Volumn 31, Issue 12, 2009, Pages 2954-2987

  Veldhorst Janssen, Nicole M L ^a   Fiddelers, Audrey A A ^a   van der Kuy, Paul Hugo M ^b   Neef, Cees ^a   Marcus, Marco A E ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

Author keywords

antimigraine drugs; benzodiazepines; nasal drug delivery; opioids; pharmacokinetics; systematic review

Indexed keywords

ALFENTANIL; ANTIMIGRAINE AGENT; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; BUTORPHANOL; BUTORPHANOL TARTRATE; CLONAZEPAM; DIAZEPAM; DIHYDROERGOTAMINE; FENTANYL; FENTANYL CITRATE; FLUTICASONE PROPIONATE; HYDROMORPHONE; HYDROXOCOBALAMIN; METHADONE; MIDAZOLAM; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; OXYMETAZOLINE; PLACEBO; PSEUDOEPHEDRINE; RIZATRIPTAN; SUFENTANIL; SUMATRIPTAN; ZOLMITRIPTAN;

ALLERGIC RHINITIS; AREA UNDER THE CURVE; CANCER PAIN; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTIPLE DRUG DOSE; NONHUMAN; POSTOPERATIVE PAIN; REPEATED DRUG DOSE; REVIEW; RHINITIS; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; VASOMOTOR RHINITIS; VITAMIN DEFICIENCY;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; AEROSOLS; BENZODIAZEPINES; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIGRAINE DISORDERS; NARCOTIC ANTAGONISTS;

EID: 74549204827     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.12.015     Document Type: Review

References (66)

1. Chien Y.W., and Chang S.F. Intranasal drug delivery for systemic medications. Crit Rev Ther Drug Carrier Syst. 4 (1987) 67-194
2. Costantino H.R., Illum L., Brandt G., et al. Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm. 337 (2007) 1-24
3. Dale O., Hoffer C., Sheffels P., and Kharasch E.D. Disposition of nasal, intravenous, and oral methadone in healthy volunteers. Clin Pharmacol Ther. 72 (2002) 536-545
4. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 87 (2003) 187-198
5. Costantino H.R., Sileno A.P., and Johnson P.H. Pharmacokinetic attributes of intranasal delivery: Case study and new opportunities. http://www.ondrugdelivery.com/publications/NASAL%20FINAL%20Lo-res.pdf Accessed April 2009
6. Micromedex. http://www.micromedex.com Accessed April 2009
7. In: Beers M.H., Porter R.S., Jones T.V., et al. (Eds). The Merck Manual of Diagnosis and Therapy. 18th ed (2006), Merck Research Laboratories, Whitehouse Station, NJ
8. Drummond M., Sculpher M., Torrance G., et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. (2005), Oxford University Press, New York, NY
9. Centre for Reviews and Dissemination. Undertaking systematic reviews on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD Report 4 (2nd edition). http://www.york.ac.uk/inst/crd/report4.htm Accessed April 2009
10. Neef C., and van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 37 (1999) 257-271
11. Coda B.A., Rudy A.C., Archer S.M., and Wermeling D.P. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg. 97 (2003) 117-123 table of contents
12. Davis G.A., Rudy A.C., Archer S.M., and Wermeling D.P. Bioavailability of intranasal butorphanol administered from a single-dose sprayer. Am J Health Syst Pharm. 62 (2005) 48-53
13. Davis G.A., Rudy A.C., Archer S.M., and Wermeling D.P. Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer. Am J Health Syst Pharm. 61 (2004) 261-266
14. Davis G.A., Rudy A.C., Archer S.M., et al. Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis. Clin Drug Investig. 24 (2004) 633-639
15. Davis G.A., Rudy A.C., Archer S.M., et al. Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. Pharmacotherapy 24 (2004) 26-32
16. Eriksen J., Jensen N.H., Kamp-Jensen M., et al. The systemic availability of buprenorphine administered by nasal spray. J Pharm Pharmacol 41 (1989) 803-805
17. Fitzgibbon D., Morgan D., Dockter D., et al. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain 106 (2003) 309-315
18. Helmers J.H., Noorduin H., Van Peer A., et al. Comparison of intravenous and intranasal sufentanil absorption and sedation. Can J Anaesth 36 (1989) 494-497
19. Illum L., Watts P., Fisher A.N., et al. Intranasal delivery of morphine. J Pharmacol Exp Ther. 301 (2002) 391-400
20. Lim S.C., Paech M.J., Sunderland V.B., et al. Pharmacokinetics of nasal fentanyl. J Pharm Pract Res. 33 (2003) 59-63
21. Rudy A.C., Coda B.A., Archer S.M., and Wermeling D.P. A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg. 99 (2004) 1379-1386
22. Schwagmeier R., Boerger N., Meissner W., and Striebel H.W. Pharmacokinetics of intranasal alfentanil. J Clin Anesth. 7 (1995) 109-113
23. Shyu W.C., Mayol R.F., Pfeffer M., et al. Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. Biopharm Drug Dispos. 14 (1993) 371-379
24. Shyu W.C., Morgenthien E.A., Pittman K.A., and Barbhaiya R.H. The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol. Eur J Clin Pharmacol. 47 (1994) 57-60
25. Shyu W.C., Pittman K.A., Robinson D., and Barbhaiya R.H. Multiple-dose phase 1 study of transnasal butorphanol. Clin Pharmacol Ther. 54 (1993) 34-41
26. Shyu W.C., Pittman K.A., Robinson D.S., and Barbhaiya R.H. The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. Eur J Clin Pharmacol. 45 (1993) 559-562
27. Takala A., Kaasalainen V., Seppälä T., et al. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol Scand. 41 (1997) 309-312
28. Vachharajani N.N., Shyu W.C., Greene D.S., and Barbhaiya R.H. The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans. Biopharm Drug Dispos. 18 (1997) 191-202
29. Wermeling D.P., Miller J.L., Archer S.M., et al. Pharmacokinetics, bioequivalence, and spray weight reproducibility of intranasal butorphanol after administration with 2 different nasal spray pumps. J Clin Pharmacol. 45 (2005) 969-973
30. Christrup L.L., Foster D., Popper L.D., et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 30 (2008) 469-481
31. Moksnes K., Fredheim O.M., Klepstad P., et al. Early pharmacokinetics of nasal fentanyl: Is there a significant arterio-venous difference?. Eur J Clin Pharmacol. 64 (2008) 497-502
32. Lim C.B., Paech M.J., Goy R., et al. Pharmacokinetics and bioavailability of hydromorphone nasal spray. J Pharm Pract Res. 38 (2008) 191-195
33. Björkman S., Rigemar G., and Idvall J. Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients. Br J Anaesth. 79 (1997) 575-580
34. Burstein A.H., Modica R., Hatton M., et al. Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. J Clin Pharmacol. 37 (1997) 711-718
35. Dale O., Nilsen T., Loftsson T., et al. Intranasal midazolam: A comparison of two delivery devices in human volunteers. J Pharm Pharmacol. 58 (2006) 1311-1318
36. Gizurarson S., Gudbrandsson F.K., Jónsson H., and Bechgaard E. Intranasal administration of diazepam aiming at the treatment of acute seizures: Clinical trials in healthy volunteers. Biol Pharm Bull. 22 (1999) 425-427
37. Gudmundsdottir H., Sigurjonsdottir J.F., Masson M., et al. Intranasal administration of midazolam in a cyclodextrin based formulation: Bioavailability and clinical evaluation in humans. Pharmazie. 56 (2001) 963-966
38. Knoester P.D., Jonker D.M., Van Der Hoeven R.T., et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol. 53 (2002) 501-507
39. Lindhardt K., Gizurarson S., Stefánsson S.B., et al. Electroencephalographic effects and serum concentrations after intranasal and intravenous administration of diazepam to healthy volunteers. Br J Clin Pharmacol. 52 (2001) 521-527
40. Loftsson T., Gudmundsdóttir H., Sigurjónsdóttir J.F., et al. Cyclodextrin solubilization of benzodiazepines: Formulation of midazolam nasal spray. Int J Pharm. 212 (2001) 29-40
41. Schols-Hendriks M.W., Lohman J.J., Janknegt R., et al. Absorption of clonazepam after intranasal and buccal administration. Br J Clin Pharmacol. 39 (1995) 449-451
42. Wermeling D.P., Record K.A., Kelly T.H., et al. Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers. Anesth Analg. 103 (2006) 344-349
43. Wermeling D.P., Record K.A., Archer S.M., and Rudy A.C. A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation. Epilepsy Res. 83 (2009) 124-132
44. Chen J., Jiang X.G., Jiang W.M., et al. Intranasal absorption of rizatriptan-in vivo pharmacokinetics and bioavailability study in humans. Pharmazie. 60 (2005) 39-41
45. Humbert H., Cabiac M.D., Dubray C., and Lavène D. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin Pharmacol Ther. 60 (1996) 265-275
46. van der Kuy P.H., Lohman J.J., Hooymans P.M., et al. Bioavailability of intranasal formulations of dihydroergotamine. Eur J Clin Pharmacol. 55 (1999) 677-680
47. Lonterman S., Van Asselt D.Z., Olde Rikkert M.G., et al. Intranasal hydroxocobalamin administration: An attractive alternative for intramuscular cobalamin injections in geriatric patients. Drug Develop Res. 51 (2000) 197-199
48. van Asselt D.Z., Merkus F.W., Russel F.G., and Hoefnagels W.H. Nasal absorption of hydroxocobalamin in healthy elderly adults. Br J Clin Pharmacol. 45 (1998) 83-86
49. Van der Kuy P.H., Merkus F.W., Russel F.G., et al. Pharmacokinetics of intranasal and oral hydroxocobalamin in healthy subjects. Br J Clin Pharmacol. 51 (2001) 505P
50. Duquesnoy C., Mamet J.P., Sumner D., and Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci. 6 (1998) 99-104
51. Moore K.H., Hussey E.K., Shaw S., et al. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia. 17 (1997) 541-550
52. Kagedal M., Zingmark P.H., Hedlund C., and Yates R. True nasopharyngeal absorption of zolmitriptan after administration via nasal spray in healthy male volunteers. Am J Drug Deliv. 3 (2005) 133-140
53. Uemura N., Onishi T., Mitaniyama A., et al. Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Investig. 25 (2005) 199-208
54. Yates R., Nairn K., Dixon R., et al. Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers. J Clin Pharmacol. 42 (2002) 1244-1250
55. Yates R., Nairn K., Dixon R., and Seaber E. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. J Clin Pharmacol. 42 (2002) 1237-1243
56. Bullingham R.E., McQuay H.J., Dwyer D., et al. Sublingual buprenorphine used postoperatively: Clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol. 12 (1981) 117-122
57. Pachter I.J., and Evens R.P. Butorphanol. Drug Alcohol Depend. 14 (1985) 325-338
58. Darwish M., Kirby M., Robertson Jr. P., et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol. 47 (2007) 343-350
59. Vallner J.J., Stewart J.T., Kotzan J.A., et al. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 21 (1981) 152-156
60. Mandema J.W., Kaiko R.F., Oshlack B., et al. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol. 42 (1996) 747-756
61. Crevoisier C., Delisle M.C., Joseph I., and Foletti G. Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. Eur Neurol. 49 (2003) 173-177
62. Friedman H., Greenblatt D.J., Peters G.R., et al. Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time. Clin Pharmacol Ther. 52 (1992) 139-150
63. Smith M.T., Eadie M.J., and Brophy T.O. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol. 19 (1981) 271-278
64. Benowitz N.L., Pérez-Stable E.J., Herrera B., and Jacob III P. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese- Americans. J Natl Cancer Inst. 94 (2002) 108-115
65. Zhou H.H., and Liu Z.Q. Ethnic differences in drug metabolism. Clin Chem Lab Med. 38 (2000) 899-903
66. Van der Kuy P.H., Lohman J.J., Veld-horst-Janssen N.M., et al. Intranasal drug delivery in migraine: State of the art. Nederlands Tijdschrift voor Neurologie. 1 (1998) 49-56